3月19日 - ** Akebia Therapeutics' <AKBA.O> 股价在延长交易时段下跌 25%，至 2.13 美元，该公司正寻求融资
** 总部位于马萨诸塞州剑桥市的生物制药公司专注于肾脏疾病，开始 (link) 股票发行；交易规模未披露
** Leerink Partners和Piper Sandler担任联合账簿管理人
** 根据伦敦证券交易所集团的数据，该公司流通股约为2.362亿股，市值约为6亿美元
** AKBA股价连续四个交易日上涨，累计涨幅达68%。周三收盘上涨11.4%，报2.84美元
** 上周四，该公司表示，预计其贫血药物 (link) （品牌名为Vafseo）将在第一季度实现1000万至1100万美元的净产品收入
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.